Crossmark

The JAK1/2 inhibitor Ruxolitinib as therapeutic option in steroid resistance, prophylaxis and frontline therapy for graft versus host disease, meta-analysis

Crossref DOI link: https://doi.org/10.1007/s44337-025-00382-x

Published Online: 2025-07-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Debes, Mohammed

Elyasaky, Amr

Abouzeid, Mohamed

Elantary, Ramy

Mahmood, Zaeem

Downey, Robert

Yassiri, Ahmed
License Information

Text and Data Mining valid from 2025-07-09

Version of Record valid from 2025-07-09
More Information

Article History

Received: 15 February 2025

Accepted: 10 June 2025

First Online: 9 July 2025

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below